Depression in breast cancer patients: Immunopathogenesis and immunotherapy

Cancer Lett. 2022 Jun 28:536:215648. doi: 10.1016/j.canlet.2022.215648. Epub 2022 Mar 17.

Abstract

Depression is a common and recurrent mental illness with a complicated etiology, but the specific pathogenesis is not clear. Breast cancer increases susceptibility to depression, which leads to a poor prognosis. Rapid advances in the understanding of tumor immunology and neuroimmunology have provided new evidence for the pathogenesis of depression. Dysfunction of immune cells and cytokines cause depression by affecting tryptophan metabolism, serotonin levels, and blood-brain barrier permeability. Dysregulation of cytokines or intestinal flora may be shared between patients with depression and breast cancer. This review presents an overview of immune dysregulation in breast cancer patients with depression and proposes future alternative research directions and interventions.

Keywords: Behavioral symptoms; Biomarkers; Cyclooxygenase inhibitors; Cytokines; Immune disorder; Murine models of depression.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / therapy
  • Cytokines
  • Depression* / metabolism
  • Female
  • Humans
  • Immunologic Factors
  • Immunotherapy
  • Serotonin / metabolism

Substances

  • Cytokines
  • Immunologic Factors
  • Serotonin